IL2 and retinoblastoma: Another report described a 9-year-old male with relapsed single bone metastatic RB treated with two cycles of dinutuximab beta with GM-CSF, aldesleukin (IL-2), and spironolactone after ASCT, demonstrating safety and no disease progression for up to 18 months post-treatment (40).